Can a drug actually cure chronic hepatitis B?
In about 1 in 5 patients, yes. In two large phase 3 trials, a drug called bepirovirsen produced a functional cure for chronic hepatitis B in about 1 in 5 patients, while no one on placebo was cured. The cure rate was 20 percent (127 of 650 patients) in the first trial and 19 percent (106 of 570) in the second, and it held even after patients stopped their daily antiviral pills.
Chronic hepatitis B is a long-term infection of the liver. For decades, doctors have told patients that it is a lifelong condition. The usual medicines can hold the virus down, but they rarely clear it. Most people take these pills every day for the rest of their lives. That is why this new result matters so much. It shows a therapy producing a functional cure in a meaningful share of people who were told the infection could not be cured.
What the trials found
The two trials were named B-Well 1 and B-Well 2. They were designed as near-identical copies of each other, which is a strong way to test whether a result is real and repeatable. Both were double-blind, meaning neither the patients nor their doctors knew who got the real drug and who got a placebo. This design helps remove bias and makes the findings more trustworthy.
Adults in the trials had chronic hepatitis B but did not have cirrhosis, which is severe liver scarring. All of them were already on stable antiviral therapy, the standard daily pills used to control the virus. On top of that treatment, they received a weekly shot under the skin of either bepirovirsen or a placebo for 24 weeks. Patients who qualified then stopped their antiviral pills at week 48. Researchers checked the results at week 72, well after the shots had stopped.
The main goal was a functional cure. That means two things happening together and lasting: the virus DNA stayed below the lowest level the test can measure for at least 24 weeks, and the patient lost the hepatitis B surface antigen, a marker that signals an active infection, all without needing rescue treatment. About 20 percent of people on bepirovirsen reached this mark, compared with 0 percent on placebo.
Dr. Kumar’s Take
I do not use the word cure lightly, and neither should anyone reading about hepatitis B. So when a phase 3 trial shows a real functional cure in roughly 1 in 5 patients, with zero cures on placebo, I pay close attention. For a disease long called incurable, that is a genuine shift in what is possible.
Here is the honest context. A functional cure is not the same as wiping every trace of the virus from the body. It means the infection is controlled so well that the standard markers of active disease disappear and stay gone. That is a huge quality-of-life change, and it can lower the long-term risk of liver damage and liver cancer. But four out of five patients did not reach that mark, so this is not a guaranteed fix for everyone. The trials also only enrolled people whose surface antigen was within a set range, so patient selection will matter a lot in real practice.
Who the results apply to
The trials enrolled a specific group. Everyone was already taking standard antiviral pills, had no cirrhosis, and had a hepatitis B surface antigen level between 100 and 3,000 IU per milliliter. The results do not show how the drug works in people outside that range or in people with cirrhosis.
The cure was also measured after patients stopped their pills. Eligible patients stopped their antiviral therapy at week 48, and the cure at week 72 counted only if the virus DNA stayed below the measurable level without those pills.
Side effects
Side effects were more common with the drug. Over 72 weeks, 91 percent of people on bepirovirsen reported an adverse event, compared with 73 percent on placebo. Serious adverse events occurred in 7 percent versus 4 percent. During the 24 weeks of shots, 16 percent on bepirovirsen had a severe (grade 3 or higher) side effect, compared with 3 percent on placebo. The most common severe one was a rise in the liver enzyme ALT, seen in 6 percent of people on the drug.
What is still unknown
These results are exciting, but a few important questions remain open. The trials measured cure at week 72, so longer follow-up is needed to confirm that the cure holds for years, not just months.
Bepirovirsen is still an investigational drug, which means it is not yet approved or available for general use. Regulators will review the complete data before deciding whether it can be prescribed. Until then, current antiviral therapy remains the standard of care, and no one should stop their existing treatment based on these headlines.
Practical Takeaways
- If you have chronic hepatitis B, keep taking your prescribed antiviral pills, because they still control the virus and this new drug is not yet approved or available.
- Ask your liver specialist about your hepatitis B surface antigen level, since these trials only enrolled people with levels between 100 and 3,000 IU per milliliter.
- Talk with your doctor about clinical trials for functional cure therapies if you are interested, as this is now an active and fast-moving area of research.
- Stay up to date on liver cancer screening and liver health checks, since long-term hepatitis B carries risks that a future cure does not automatically erase.
Related Studies and Research
- Finerenone slows kidney decline in people without diabetes
- Long Daytime Naps Linked to Worse Thinking in Older Adults
- A weekly shot for type 2 diabetes that also drops 14% of body weight
FAQs
What is a functional cure for hepatitis B?
A functional cure does not mean every last virus particle is gone from the body. It means the infection is controlled so completely that the usual signs of active disease disappear and stay away. In these trials, that meant the virus DNA stayed below the lowest measurable level and the hepatitis B surface antigen was lost, without any need for rescue treatment. This is a meaningful goal because it lowers the risk of liver damage and can free some patients from the burden of lifelong daily medication.
How is bepirovirsen given, and for how long?
In the B-Well trials, patients received bepirovirsen as a shot under the skin once a week for 24 weeks. Importantly, they took it on top of their standard antiviral pills, not instead of them. Eligible patients stopped those pills at week 48. After the 24 weeks of shots ended, researchers kept following patients and measured the cure rate at week 72. That gap between stopping the drug and checking results helps show whether the effect lasts rather than fading right away.
Can I get bepirovirsen from my doctor right now?
Not yet. Bepirovirsen is still an investigational drug, which means it has completed these large trials but has not been approved for everyday use. Health regulators need to review the full safety and effectiveness data before deciding whether doctors can prescribe it. For now, the standard daily antiviral medicines remain the proven way to control chronic hepatitis B, and you should not change your treatment without talking to your doctor.
Bottom Line
For a disease long considered incurable, this is a real turning point. Two large, well-designed phase 3 trials showed that bepirovirsen produced a functional cure in about 1 in 5 people with chronic hepatitis B, while no one on placebo was cured. The drug is not approved yet, and longer follow-up is needed to confirm the cure lasts, but a therapy has now produced a functional cure in a meaningful share of patients who were told this infection never could be cured.
